Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical Sciences, Small Animal Clinical Sciences Department will be presenting at the Veterinary Cancer Society ("VCS") Annual Conference in Houston taking place this weekend. The VCS Conference is one of the largest veterinary oncology meetings in the world with presentations from keynote speakers, basic science and clinical science abstracts and poster sessions, in addition to technician workshops.
Dr. Wilson-Robles' presentation entitled "Detection of nucleosomes in the blood of canines with cancer and inflammation" will take place on Saturday, October 19 at 9:15 a.m. CDT.
Dr. Wilson-Robles commented: "I am delighted to have the opportunity to introduce the potential use of the Nu.Q(TM) technology to the veterinary oncology community at this prestigious event. It is exciting to share some of the encouraging early work we have done together with Volition. This pre-analytical work was important to allow us to plan the product development program for Nu.Q(TM) Vet. I believe the early identification of cancer has the potential to significantly impact veterinary oncology as we know it and thereby look forward to developing Nu.Q(TM) Vet further."
Nathan Dewsbury, Chief Executive Officer of Texas-based Volition Veterinary Diagnostics Development LLC will also be in attendance at the meeting. Commenting on the conference, Mr. Dewsbury noted: "There are currently no accurate, simple, affordable cancer screening tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage in their lives. At Volition Veterinary we believe that early diagnosis is the key and are working hard to develop Nu.Q(TM) Vet products which can simply and affordably help diagnose cancer and a range of other diseases through a routine blood draw. I am delighted to attend this conference and look forward to meeting veterinary oncologists involved in private practice, academic practice as well as those who participate in research and development."
Members of the Volition Board and Executive Management are visiting the Texas A&M College of Veterinary Medicine & Biomedical Sciences Campus with members of the Belgian AWEX delegation on October 25, 2019.
About the Veterinary Cancer Society
VCS is a non-profit educational organization consisting of nearly 1000 specialists in medical, surgical, and radiation oncology, internists, pathologists, pharmacologists and general practitioners from around the world. Professionals, students, residents, interns and technicians all form the membership of the Veterinary Cancer Society today.
The focus of the organization is to encourage research and collaboration among its members. Each fall, the Veterinary Cancer Society holds an annual conference, one of the largest veterinary oncology meetings in the world.
Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics(TM), which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
For more information about Volition, visit Volition's website (http://www.volition.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Batchelor, Volition
+44 (0)7557 774620
Scott Powell, Volition
+1 (646) 650 1351
Joseph Green, Edison Advisors
+1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's blood-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics(TM) and Nu.Q(TM) and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
SOURCE VolitionRx Ltd
Released October 18, 2019